DMAC Overview

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Wall Street analysts forecast DMAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMAC is17.00 USD with a low forecast of 12.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

DiaMedica Therapeutics Inc revenue for the last quarter amounts to -9.21M USD, increased 9.43

DiaMedica Therapeutics Inc. EPS for the last quarter amounts to -7771000.00 USD, increased 20.65

DiaMedica Therapeutics Inc (DMAC) has 35 emplpoyees as of April 21 2026.

Today DMAC has the market capitalization of 353.47M USD.